UBS: Upgrades Shanghai Pharmaceuticals Holding (02607) target price to HK$15.2, rating "buy"

UBS released a research report stating that Shanghai Pharmaceuticals Holding (02607) saw a 3% year-on-year increase in total revenue to 284 billion yuan last year, with net profit rising by 25.7% to 5.72 billion yuan, while recurring net profit fell by 26.7% to 2.98 billion yuan, roughly in line with expectations. The earnings forecast for Shanghai Pharmaceuticals Holding for the years 2026 to 2028 has been adjusted by 1% to 3% upward, with the target price raised from HK$15 to HK$15.2, and a "buy" rating. The report points out that considering Shanghai Pharmaceuticals Holding's positioning strategy, diversified business, and competitive advantages in fast-growing sectors, UBS expects that Shanghai Pharmaceuticals Holding's growth during the "13th Five-Year Plan" period will surpass that of its pharmaceutical distribution peers.